Anti-VEGF Anticancer Drugs: Mind the Hypertension

Area of Science:

• Oncology
• Pharmacology
• Cardiology

Background:

• Vascular endothelial growth factor inhibitors (VEGFi) have transformed cancer therapy by targeting tumor angiogenesis.
• While effective, VEGFi therapy poses safety concerns, particularly with long-term use.
• Hypertension (HTN) is a significant adverse effect associated with VEGFi treatment, complicating patient management.

Purpose of the Study:

• To review the association between VEGFi agents and the manifestation of hypertension.
• To explore the potential risks linked to VEGFi-induced hypertension.
• To propose prevention strategies and therapeutic approaches for managing hypertension in patients receiving VEGFi therapy.

Main Methods:

• Literature review of studies investigating VEGFi and hypertension.
• Analysis of reported risks and complications associated with VEGFi-induced HTN.
• Synthesis of current knowledge on prevention and management strategies.

Main Results:

• VEGFi therapy is strongly linked to the development of hypertension.
• Managing VEGFi-induced HTN is challenging, with optimal strategies still under investigation.
• Understanding risks and implementing monitoring are crucial for patient safety.

Conclusions:

• Effective management of VEGFi-associated hypertension is critical for optimizing cancer treatment outcomes.
• Proactive blood pressure monitoring and tailored therapeutic interventions are essential.
• Further research is needed to establish definitive management guidelines for VEGFi-induced HTN.